Comparative Pharmacology
Head-to-head clinical analysis: EMCYT versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMCYT versus VIVIMUSTA.
EMCYT vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Alkylating Agent
Alkylating Agent